EGFR and adenocarcinoma: An intriguing aspect of our case is the “evolution” of the tumor first to a pure squamous histology in the brain metastatic site in the absence of any selective pressure by an EGFR tyrosine kinase inhibitor followed by a later local recurrence with pure adenocarcinoma histology.